// App-Quantinova.ai

Tu1914 : SHOULD WE RECOMMEND ANTI- CLOSTRIDIUM DIFFICILE ANTIBIOTIC OR PROBIOTIC PROPHYLAXIS?: RISK OF CLOSTRIDIUM DIFFICILE INFECTION WITH SYSTEMIC ANTIMICROBIAL THERAPY FOLLOWING SUCCESSFUL FECAL MICROBIOTA TRANSPLANT

Researchers

Presenter

  • Dina H. Kao

Principal Investigators

  • Emmalee L. Phelps

  • Justin D. Smith

  • Brandi Roach

  • Zain Kassam

  • Huiping Xu

  • Jessica R. Allegretti

Medical Centers

  • MGH HMS, Boston, Massachusetts, United States

  • Indiana University-Purdue University Indianapolis, Indianapolis, Indiana, United States

  • Brigham and Womens Hospital, Brookline, Massachusetts, United States

  • Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, United States

  • University of Alberta Hospital, Edmonton, Alberta, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Amoclan suspension

  • Fluoroquinolone

  • Clavulanic acid

  • Metronidazole

  • Fidaxomicin

  • Amoxicillin

  • vancomycin capsule

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved